



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313-1450, on 3-24-04

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By Tracie Brooks
Tracie Brooks

Attorney Docket No. 316E-001510US
Client Ref. No. GALO-015/01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Jennifer L. Whistler, et al.

Application No.: 10/622,373

Filed: July 18, 2003

For: METHODS AND COMPOSITIONS
FOR MODULATING AGONIST-
INDUCED DOWNREGULATION OF
G PROTEIN-COUPLED
RECEPTORS

Examiner: Unassigned

Art Unit: 1646

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Gwynedd Warren, Ph.D.
Reg. No. 45,200

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


5

Application Number	10/622,373
Filing Date	July 18, 2003
First Named Inventor	Jennifer L. Whistler
Group Art Unit	1646
Examiner Name	Unassigned
Total Number of Pages in This Submission	316E-001510US

ENCLOSURES (check all that apply)


<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Gwynedd Warren, Reg. No. 45,200, Quine Intellectual Property Law Group, P.C.
Signature	
Date	3/24/04

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Tracie Brooks		
Signature		Date	3-24-04

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A-B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p> <p><i>MAR 26 2004</i></p> <p><i>PATENT & TRADEMARK</i></p>		Complete if Known	
		Application Number	10/622,373
		Filing Date	July 18, 2003
		First Named Inventor	Jennifer L. Whistler
		Group Art Unit	1646
		Examiner Name	Not yet assigned
		Attorney Docket Number	316E-001510US
Date Submitted	March 24, 2004		

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appeal	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					T
1	C.J. Evans, et al., Science 258, 1952-5 (1992)						
2	Cao, T.T. et al., Nature 401, 286-90 (1999)						
3	Chaturvedi, K. et al. J Biol Chem 276, 12345-55 (2001)						
4	Cong, M. et al., J Biol Chem 276 45145-52 (2001)						
5	Ferguson, S.S. et al. Life Sciences 62, 1561-5 (1998)						
6	Finn, A.K., et al. Neuron 32, 829-39 (2001)						
7	Gage, R.M. et al. J Biol Chem 276, 44712-20 (2001)						
8	Gagnon, A.W., et al. J Biol Chem 273, 6976-81 (1998)						
9	Goodman, O.B., Jr., et al., Adv Pharmacol 42, 429-33 (1998)						
10	Heck, D.A., et al, J Pharmacol Exp Ther 282, 1219-27 (1997)						
11	Innamorati, G., et al. Proc Natl Acad Sci USA 95, 2222-6 (1998)						
12	Kaufman D.L. et al., Journal of Biological Chemistry 270, 15877-15883 (1995)						
13	Keith, et al., J Biol Chem 271, 19021 (1996)						
14	Klein, U., J Biol Chem 272, 19099-102 (1997)						

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTMAR 26 2004
(use as many sheets as necessary)

Application Number	10/622,373
Filing Date	July 18, 2003
First Named Inventor	Jennifer L. Whistler
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	316E-001510US
Date Submitted	March 24, 2004

15	Law, P.Y. et al J Pharmacol Exp Ther 289, 607-24 (1999)
16	Lefkowitz, R.J., et al., Adv Pharmacol 42, 416-420 (1998)
17	M. Suyama, et al., NucleicAcids Res 27, 338-9 (1999)
18	Petaja-Repo, U.E., et al., J Biol Chem 276, 4416-23 (2001)
19	Peterson, M.G., Science 248, 1625-30 (1990)
20	Shenoy, S.K., et al. Science 294, 1307-13 (2001)
21	Trejo, J., et al. J Biol Chem 274, 2216-24 (1999)
22	Tsao, P. et al. Curr Opin Neurobiol 10, 365-9 (2000)
23	Tsao, Patricia L. and von Zastrow, Mark J Biol Chem, Vol. 275 11130-11140, (2000)
24	von Zastrow, Mark, et al., J Biol Chem 267, 3530-8 (1992)
25	Wang, H. (et al.) J Neurosci 21, 3242-50 (2001)
26	Wang, Y.X., et al. J Cell Biol 140, 1063-74 (1998)
27	Whistler, J.L., et al. Proc Natl Acad Sci USA 95, 9914-9 (1998)
28	Whistler, J.L., et al., J Biol Chem 276, 34331-8 (2001).
29	Yaksh, T.L., J Pharmacol Exp Ther 226, 303-16 (1983).
30	Zhang, J. et al., Proceedings of the National Academy of Sciences of the United States of America 95, 7157-62 (1998)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.